ERBB2 and breast cancer: The current findings in the treatment of breast cancer showed that CK0403 was more potent and effective than CK0402 against estrogen receptor-negative and HER2-overexpressing breast cancer cell lines, implying that it could be used as a breast cancer chemotherapy in the future [36].